What is Hologic Diagenode?
Founded in 2003 and headquartered in Wallonia, Belgium, Diagenode operates as a specialized subsidiary of Hologic, focusing on the development of high-precision sample preparation products. The company serves as a vital link in the research value chain, providing essential tools for next-generation sequencing (NGS), proteomics, and epigenetics. By streamlining complex laboratory workflows, Diagenode enables researchers to achieve higher reproducibility and sensitivity in their experimental outcomes. Its integration into the Hologic ecosystem has further expanded its reach, allowing the firm to leverage broader distribution networks while maintaining its commitment to technical excellence in the epigenetics domain.
How much funding has Hologic Diagenode raised?
Hologic Diagenode has raised a total of $8.5M across 1 funding round:
Other Financing Round
$8.5M
Other Financing Round (2016): $8.5M with participation from Epimede SA, Capricorn Health-tech Fund NV, SRIW SA, SpinVenture, OBI SA, and Societe Regionale d'Investissement de Wallonie
Key Investors in Hologic Diagenode
SRIW SA
Wallonie Entreprendre is the economic and financial tool of Wallonia, dedicated to supporting the entrepreneurial fabric of the region through financing, guarantees, and expertise.
Capricorn Health-tech Fund NV
A venture capital firm specializing in early-stage and growth-stage investments within the healthcare and life sciences technology sectors.
Epimede SA
An investment entity focused on providing strategic capital to innovative companies within the European technology and life sciences landscape.
What's next for Hologic Diagenode?
With the infusion of capital from its latest financing round, Hologic Diagenode is well-positioned to accelerate its product development pipeline and expand its footprint in the global genomics market. The strategic focus will likely shift toward enhancing automation in sample preparation, a key bottleneck in high-throughput sequencing environments. Furthermore, the company is expected to deepen its investment in proprietary epigenetics technologies, aiming to capture a larger share of the clinical diagnostics and translational research markets. As the industry moves toward more personalized medicine, Diagenode's ability to provide robust, scalable solutions will be a primary driver of its long-term growth trajectory and competitive differentiation.
See full Hologic Diagenode company page
